On January 24, 2022, Harvard Bioscience, Inc. accepted the resignation of Ken Olson for personal reasons from his position as Chief Operating Officer of the Company effective January 31, 2022. Mr. Olson will assist on various projects and in the transition of the Chief Operating Officer role until his departure from the Company on December 31, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 USD | -2.62% | -5.90% | -37.38% |
May. 07 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.38% | 149M | |
+12.15% | 228B | |
+14.90% | 196B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 65.88B | |
+16.92% | 54.3B | |
+6.33% | 52.39B | |
+10.93% | 45.22B | |
+5.87% | 37.12B |
- Stock Market
- Equities
- HBIO Stock
- News Harvard Bioscience, Inc.
- Harvard Bioscience, Inc. Announces Executive Changes